REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Reviva Pharmaceuticals Holdings, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 13.11M shares outstanding
USReviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to advancing novel therapeutic solutions.
The company strives to identify, develop, and commercialize treatments that address significant unmet medical needs across various therapeutic areas, including disorders of the central nervous system, respiratory conditions, cardiovascular issues, metabolic syndromes, and inflammatory diseases.
Its primary investigational drug, RP5063, is currently undergoing Phase III clinical trials for the treatment of schizophrenia. This compound has also completed Phase I studies exploring its potential in a broad range of other conditions, such as bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic manifestations associated with dementia or Alzheimer's, Parkinson's disease-related psychosis, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.
Additionally, Reviva is developing RP1208, a preclinical candidate targeting both depression and obesity.
The company's operations are based in Cupertino, California.
Leadership
Laxminarayan Bhat
Founder, Chief Executive Officer, President & Director
Les Funtleyder
Director
Parag Saxena
Chairman of the Board
Purav Patel
Director
Employees
14
Country
US
Sector
Healthcare
Website
revivapharma.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Prabhu Narayan | Chief Financial Officer | Grant/Award | 40.9K | -- | Mar 18, 2026 |
 Bhat Laxminarayan | President and CEO | Grant/Award | 109.2K | -- | Mar 18, 2026 |
| Bhat Laxminarayan | President and CEO | Grant/Award | 40.9K | -- | Mar 18, 2026 |
 Funtleyder Leslie D. | Director | Grant/Award | 8.2K | -- | Dec 18, 2025 |
 SAXENA PARAG | Director | Grant/Award | 8.2K | -- | Dec 18, 2025 |
 Patel Purav | Director | Grant/Award | 8.2K | -- | Dec 18, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
Integrated Core Strategies (US) LLC · joint filing· may incl. warrants· filed Aug 2026 | 1.1M | 8.2% | 13G |
CVI Investments, Inc. · joint filing· may incl. warrants· filed May 2026 | 672.8K | 5.1% | 13G |
EMC Capital Management | 6.7K | 0.1% | 13F |
Purpose Unlimited Inc. | 405 | 0.0% | 13F |
Miller Global Investments, LLC | 1 | 0.0% | 13F |
Insiders
- Prabhu NarayanChief Financial Officer
- Bhat LaxminarayanPresident and CEO
- Funtleyder Leslie D.Director
- SAXENA PARAGDirector
- Patel PuravDirector
- Margolin Richard ADirector
Top institutional holders
based on 13.11M shares outstanding
US30d Avg
32.34K
60d Avg
27.50K
90d Avg
29.56K